LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+24.76%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$724M
AUM Growth
+$724M
(+3.6%)
Cap. Flow
-$84M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
51.97%
Holding
60
New
17
Increased
7
Reduced
18
Closed
10
Top Buys
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$21.5M |
| 2 |
Arcellx
ACLX
|
$15.8M |
| 3 |
Arcus Biosciences
RCUS
|
$15.2M |
| 4 |
Cytokinetics
CYTK
|
$13M |
| 5 |
Annexon
ANNX
|
$12.3M |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$43.5M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$37M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$24.1M |
| 4 |
Ascendis Pharma
ASND
|
$16.1M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$15.9M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Ascendis Pharma
ASND
$12.2B
| – | – |
-150,000
| Closed | -$16.1M |
|
52
Biohaven
BHVN
$1.73B
| – | – |
-700,000
| Closed | -$9.56M |
|
53
FibroGen
FGEN
$49.9M
| – | – |
-300,000
| Closed | -$5.6M |
|
54
Disc Medicine
IRON
$2.2B
| – | – |
-525,000
| Closed | -$11.1M |
|
55
Madrigal Pharmaceuticals
MDGL
$9.65B
| – | – |
-50,000
| Closed | -$12.1M |
|
56
Mineralys Therapeutics
MLYS
$1.93B
| – | – |
-300,000
| Closed | -$4.7M |
|
|
CBAY
57
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-400,000
| Closed | -$3.49M |
|
|
DICE
58
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-410,000
| Closed | -$11.7M |
|
|
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-1,520,000
| Closed | -$37M |
|
60
Aligos Therapeutics
ALGS
$75.1M
| – | – |
-1,000,000
| Closed | -$874K |
|